SpyGlass Pharma, Inc. SGP
—
27.07
(0.58)
(2.10%)
as of 25 Sep
- Market cap
- $924.8M
- P/E
- 0.0×
Follow SGP
Insider Buys
alert about insiders buying in the last 12 month
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Current Ratio |
25.56 | 2.23 | 12.67 |
Net Debt/EBITDA |
2.86 | 0.61 | 2.63 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.92 | 0.76 | 0.82 |
Capex/Depreciation |
(1.76) | (7.35) | (1.29) |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| 0.00% | 62.41% | 50.05% | |
| 0.00% | (90.48%) | (57.29%) | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(33.74%) | (247.51%) | (38.89%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(7.19) | (13.43) | (15.11) |
Cash per Share |
23.20 | 9.10 | 48.46 |
Shareholders Equity per Share |
(18.98) | (33.82) | (44.58) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(18.98) | (33.82) | (44.58) |
Free Cash Flow |
(12.49) | (24.02) | (33.49) |
Working Capital |
39.03 | 9.62 | 100.18 |
Capital Expenditures |
(0.22) | (1.99) | (0.79) |
Net Current Asset Value |
(33.52) | (66.39) | (105.93) |
| Other line items | |||
Quick Ratio |
25.45 | 2.14 | 12.57 |
Depreciation/Fixed assets |
0.27 | 0.13 | 0.26 |
Cash ROIC |
(173.59%) | 54.73% | (407.49%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(7.06) | (12.32) | (14.75) |
Capex per Share |
(0.12) | (1.11) | (0.36) |
Average Receivables |
— | 0.27 | 0.43 |
Average Payables |
— | 1.31 | 2.34 |
Average Assets |
— | 32.23 | 69.59 |
Average Common Equity |
— | (46.73) | (79.66) |
Capex to Sales |
0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% |
Columns are period end dates